PharmAthene appoints acting chief scientific officer

PharmAthene, Inc., an Annapolis, Maryland-based pharmaceutical company, appointed Arthur Y. Elliott as its acting chief scientific officer on Friday after the abrupt resignation of the company's former chief scientific officer.

Thomas Fuerst notified PharmAthene of his resignation effective on Friday. The then quickly appointed Elliot. Elliot, an infectious disease and vaccine specialist, has been a scientific adviser to the pharmaceutical company since June 2011.

Prior to joining PharmAthene as an adviser, Elliot was a branch chief of the U.S. government's Anthrax Vaccine Portfolio within the Chemical, Biological, Radiological and Nuclear division of the Biomedical Advanced Research and Development Authority. Between 2006 and 2010, Elliot led the Avian Influenza Pandemic Program, a part of the Department of Health and Human Services. The program was a collaboration between four government agencies and multiple companies to accelerate the stockpiling of pandemic influenza vaccine for the national stockpile.

Elliot was an on-site consultant to Aventis Pharmaceutical Corporation between 2000 and 2006, advising the company on the creation of new manufacturing facilities for influenza vaccine production. Between 1994 and 1999, Elliot was the COO, senior vice president and eventually the acting president at North American Vaccine, Inc.

Elliot also worked for 16 years with Merck & Co., Inc. and was an associate urologic surgery and microbiology professor at the University of Minnesota. He earned his Ph.D. in virology from Purdue University and has an M.S. in microbiology and a B.A. in biology from North Texas State University.